




Ovarian Cancer market



Ovarian cancer is the seventh most common form of cancer and the eighth leading cause of deaths in women in the world.

In 2018, there were approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the United States.

The launch of potential emerging therapies such as OTL 38 (On Target Laboratories), 2X-121 (Oncology Venture), PX-Survivac (IMMUNOVACCINE INC), Oregovomab (OncoQuest Inc.), HPN536 (Harpoon Therapeutics), Mirvetuximab soravtansine (IMGN853, ImmunoGen, Inc.) and PRGN-3005 UltraCAR-T (Precigen) are expected to change the treatment landscape of ovarian cancer in the coming years.

For more details visit:

<https://www.delveinsight.com/blog/ovarian-cancer-market/>